Armata Pharmaceuticals, Inc. (NYSEAM: ARMP)
Health Care · Biotechnology · US
$5.36
+5.10% today · +96.2% 1Y
Armata Pharmaceuticals, Inc. (NYSEAM: ARMP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $189.63M and employs 61 people.
Over the last twelve months the share price has gained 96.2%, trading between 2.40 and 16.34.
Tweenvest scores Armata Pharmaceuticals, Inc. across four factors: quality 9/100, value 43/100. Its strongest factor is value.
ARMP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $189.63M
- Revenue (TTM)
- $5.54M
- P/E
- —
- EPS
- -5.27
- Dividend yield
- —
- Beta (5Y)
- 1.33
- 52-week high
- $16.34
- 52-week low
- $2.40
- Avg volume (3M)
- —
- Shares outstanding
- 37.18M
- Employees
- 61
- Next earnings
- —
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
- ISIN
- US04216R1023
- Listed since
- May 20, 1994
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.65 | -1.56% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.38 | -0.19% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.68 | -0.06% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.29 | -0.64% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $822.42 | -1.34% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $147.20 | -7.32% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.